DAY ONE | MONDAY, JULY 23
8:15 REGISTRATION & MORNING COFFEE
9:00 CHAIRPERSON’S OPENING REMARKS
9:15 REMAINING COMPETITIVE THROUGH CONSISTENT ASSESSMENT OF SCIENTIFIC ADVANCEMENTS
- Innovation through technical advancement from Discovery to life cycle management
- Examples for changing the paradigm of drug discovery and development using new technologies
- The role of project management within these approaches
Maria Wiekowski, Head of Project Management, SANOFI
10:00 OPPORTUNITIES AND PROCEDURES FOR COMPREHENSIVE PORTFOLIO RISK MANAGEMENT
Adequate risk management is a top tier concern for portfolio teams, and pharmaceutical risk can manifest in a variety of ways from increased costs associated with product development, changes in regulatory requirements, and unexpected resource allocation needs. As manufacturers invest a large portion of capital in emerging therapies to ensure streamlined and efficient clinical development, it is critical for portfolio management teams to continually monitor risk level in order to ensure new therapies will garner strong ROI post-launch. Creating and leveraging strategic alliances, utilizing technology to predict risk and portfolio diversification are all potential tactics for an organization to minimize risk and foster portfolio success.
- Tools to determine resource allocation for potential risk
- Analyzing amount and quality of risk in current portfolio
- Impact of big data and predictive analytics on risk management
Melanie Yevilov, Risk and Project Portfolio Management, GENENTECH
10:45 COFFEE & NETWORKING BREAK
11:15 ACHIEVING A STEP JUMP IN PORTFOLIO DELIVERY WITH REAL-TIME SCHEDULES
Good portfolios are just dreams unless they are delivered. Portfolio execution is key area where pharmaceutical companies can improve their time to market and increase the number of projects completed each year. This session by Tocio lifetime achievement award honoree, Sanjeev Gupta will reveal R&D case studies from pharma/biotech on how to accelerate project execution by 20% to 50% – while increasing the number of projects completed by 10% to 30%.
- Why project and resource scheduling is as an important lever as portfolio selection
- Why you need to replace static plans with real-time schedules
- Planning and execution best practices required to leverage real-time schedules
Sanjeev Gupta, CEO, REALIZATION TECHNOLOGIES
12:00 PRICE EROSION IN THE MARKETPLACE AND STRATEGIES TO REMAIN COMPETITIVE
Anu Raina, Associate Director PMO & Portfolio Management, PURDUE PHARMA
12:45 LUNCHEON FOR ALL CONFERENCE PARTICIPANTS
2:00 PORTFOLIO DECISION-MAKING – HIGH RISK VERSUS LOW RISK STRATEGIES
This presentation will examine a case study of a small portfolio of R&D assets in which decision-makers are faced with recommending one or other portfolio that best meets the temporal goals of the organization. Not surprisingly, based on the risk tolerance and preference of decision-makers as well as an explicit definition of what constitutes a ‘successful portfolio’, a truly dominant portfolio may not exist making it difficult, but certainly not impossible, for a portfolio decision to be rendered.
- Strategic intent.
- Risk tolerance and risk preference.
- Temporal goals.
- Resource allocation by TA/BU/sector.
- Discretionary and non-discretionary investments.
Richard Baynay, Adjunct Faculty, UNIVERSITY OF PENNSYLVANIA
2:45 UPCOMING REGULATORY CHANGES AND IMPACT ON PORTFOLIO STRATEGY
Alan Klein, Partner, DUANE MORRIS
3:30 COFFEE & NETWORKING BREAK
4:00 THE HUMAN SIDE OF DECISION MAKING: ENSURING PORTFOLIO ASSESSMENTS ARE DATA DRIVEN
Brian Lewis, Senior Director Global Portfolio Management, SHIONOGI, INC
4:45 ANALYZING AND IMPLEMENTING ORGANIZATION SPECIFIC PORTFOLIO DIVERSIFICATION
Todd Johnson, Director, Head of Portfolio Planning, GENENTECH
5:30 END OF DAY ONE CONFERENCE